More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$574615202
EPS
-2.98
P/E ratio
--
Price to sales
--
Dividend yield
--
Beta
0.649554
Previous close
$7.67
Today's open
$7.81
Day's range
$7.03 - $8.07
52 week range
$3.76 - $15.15
show more
CEO
Michael Halstead
Employees
100
Headquarters
Toronto, Ontario
Exchange
NASDAQ Global Market
Shares outstanding
79807667
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Helus Pharma's psychedelic depression drug succeeds in late-stage study
Helus Pharma said on Monday its experimental psychedelic drug showed statistically significant improvement in depression symptoms compared with placebo in a late-stage trial in patients with major depressive disorder.
Reuters • Nov 16, 2026

Helus Pharma Reports Second Quarter Fiscal 2027 Financial Results and Recent Business Highlights
Appointed Michael Halstead as Chief Executive Officer to lead Helus Pharma through late-stage development and commercialization Completed enrollment in the Phase 3 APPROACH pivotal study of HLP003 in major depressive disorder (“MDD”); topline data remains on track for Q4 2026 1 , 2 Announced design of upcoming HLP004 Phase 2 monotherapy study in generalized anxiety disorder (“GAD”); expected to initiate in Q1 2027 1 ,2 Appointed Dr. Suresh Durgam, former Executive Vice President and Chief Medical Officer of Intra-Cellular Therapies, Inc. to the Company's Board of Directors Appointed Helus Pharma board member, Mark Lawson, independent Chair of the Board of Directors This news release constitutes a “designated news release” for the purpose of the Company's prospectus supplement dated December 30, 2025, to its short form base shelf prospectus dated September 17, 2025, as amended on December 19, 2025. NEW YORK and TORONTO, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Helus Pharma Inc. (Nasdaq: HELP) (Cboe CA: HELP) (the “Company” or “Helus Pharma”), a clinical-stage pharmaceutical company committed to improving the treatment landscape in mental health through the development and commercialization of novel serotonergic agonists (“NSAs”), today reported recent business highlights and financial results for its fiscal quarter ended September 30, 2026.
GlobeNewsWire • Nov 16, 2026

Helus Pharma Touts Positive Data for Depression Drug
Helus Pharma Inc. (NASDAQ:HELP) reported topline results from its pivotal Phase 3 APPROACH trial, showing its novel serotonergic agonist HLP003 rapidly and durably reduced symptoms in adults with major depressive disorder.
Benzinga • Nov 16, 2026

Helus Pharma Announces Positive Topline Results from Phase 3 APPROACH Study evaluating HLP003 as Adjunctive Treatment in Major Depressive Disorder
HLP003 achieved statistically significant and clinically meaningful results in the primary and key secondary endpoints starting as early as Day 2 and maintained at all time points -7.6 point placebo-adjusted change from baseline at Week 6 for the primary endpoint on the Montgomery-Asberg Depression Rating Scale (“MADRS”) (p< 0.0001) Durable effect maintained through Week 12 (key secondary endpoint) with a -7.0 point placebo-adjusted change from baseline on the MADRS (p< 0.0001) Robust and statistically significant response and remission rates starting as early as Day 2 and maintained at all time points HLP003 was generally well-tolerated This news release constitutes a “designated news release” for the purpose of the Company's prospectus supplement dated December 30, 2025, to its short form base shelf prospectus dated September 17, 2025, as amended on December 19, 2025. Company to host webcast at 8:00 AM ET today NEW YORK and TORONTO,, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Helus Pharma Inc. (Nasdaq: HELP) (Cboe CA: HELP) (“Helus Pharma” or the “Company”), a clinical-stage pharmaceutical company committed to improving the treatment landscape in mental health conditions through the development and commercialization of novel serotonergic agonists (“NSAs”), today announced positive topline results from APPROACH, its Phase 3 pivotal study evaluating HLP003 (deuterated psilocin), as an adjunctive treatment for adults with major depressive disorder (“MDD”).
GlobeNewsWire • Nov 16, 2026

Helus Pharma to Present Topline Results from Phase 3 APPROACH Study Evaluating HLP003 as Adjunctive Treatment in Major Depressive Disorder on November 16, 2026
Company to host webcast at 8:00 a.m. EDT on Monday, November 16, 2026 Company to host webcast at 8:00 a.m. EDT on Monday, November 16, 2026
GlobeNewsWire • Nov 15, 2026

Cybin Expects Key Phase III Depression Trial Results This Quarter
Helus Pharma expects results from the first Phase III trial of its experimental adjunctive treatment for major depressive disorder later this quarter, CEO Michael Halstead said at the Guggenheim Healthcare Innovation Conference.
MarketBeat • Nov 10, 2026

Helus Pharma to Participate in the Guggenheim Healthcare Innovation Conference
CEO Michael Halstead to participate in a fireside chat on November 9, 2026 at 3:00 p.m. EDT CEO Michael Halstead to participate in a fireside chat on November 9, 2026 at 3:00 p.m. EDT
GlobeNewsWire • Nov 3, 2026

Helus Pharma Announces Co-Founders' Transition from Executive Leadership as Company Advances Toward Next Stage of Development
Co-founders to step down from executive roles and continue to serve on the Board of Directors Helus Pharma board member, Mark Lawson, appointed as new independent Chair of the Board of Directors, effective immediately This news release constitutes a “designated news release” for the purpose of the Company's prospectus supplement dated December 30, 2025, to its short form base shelf prospectus dated September 17, 2025, as amended on December 19, 2025. NEW YORK and TORONTO, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Helus Pharma Inc. (Nasdaq: HELP) (Cboe CA: HELP) (the “Company” or “Helus Pharma”), a clinical-stage pharmaceutical company committed to improving the treatment landscape in mental health through the development of novel serotonergic agonists (“NSAs”), today announced that co-founders Eric So and Paul Glavine have stepped down from their respective executive and consulting roles while continuing to serve as members of Helus Pharma's Board of Directors.
GlobeNewsWire • Oct 27, 2026

Cybin Eyes Q4 Phase III Depression Data as Anxiety Program Advances
Cybin NASDAQ: HELP outlined plans for two late-stage mental health programs, with top-line data from its Phase III APPROACH study of HLP003 in major depressive disorder expected later in the fourth quarter of 2026.
MarketBeat • Oct 21, 2026

Helus Pharma Inc. (HELP) Discusses Clinical Pipeline and Phase 3 Strategies for Novel Serotonergic Agonists in Mental Health Transcript
Helus Pharma Inc. (HELP) Discusses Clinical Pipeline and Phase 3 Strategies for Novel Serotonergic Agonists in Mental Health Transcript
Seeking Alpha • Oct 21, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Helus Pharma Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.